Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Nuvation Bio Inc.NYSE: NUVB

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity falls 31.9% from a year ago

Total equity stood at $253.86M at the end of Q2 FY2026, down 31.9% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at -22.4% a year.

Context

  • Total equity amounted to 34.1% of total assets at the end of Q2 FY2026, down 23.5 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -31.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$253.86M-20.6% QoQ
Last fiscal yearDec 2025
$305.72M-34.1% YoY
Year agoJun 2025
$372.91M-31.9% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.9%——
1 year-34.1%——
3-year CAGR-22.4%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
305.72M USD
Year-over-year change
-34.1%
4-year CAGR
-20.0%

Total Equity vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's Jun 2026 total equity of $253.86M is the 10th highest of the 11 companies compared; the peer median is $655.78M.
  • Its year-over-year change of -31.9% is the lowest of 11, against a peer median of +52.0%.
  • Total equity amounts to 34.1% of total assets for NUVB, versus a peer median of 78.5%.
NUVB Competitors Peer median
Total Equity for NUVB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EWTXEdgewise Therapeutics, Inc.Sep 2026$1.63B +192.3%+14.6%91.7%
GPCRStructure Therapeutics Inc.Jun 2026$1.35B +75.4%—95.0%
ABCLAbCellera Biologics Inc.Sep 2026$1.06B +10.2%-7.8%70.8%
JANXJanux Therapeutics, Inc.Mar 2026$941.54M -7.0%+44.0%91.6%
VRDNViridian Therapeutics, Inc.Jun 2026$662.1M +28.5%+22.3%60.3%
CLDXCelldex Therapeutics, Inc.Sep 2026$649.47M +8.5%+17.4%90.0%
AUPHAurinia Pharmaceuticals Inc.Jun 2026$614.86M +83.4%+12.8%77.6%
OCULOcular Therapeutix, Inc.Mar 2026$581.57M +118.7%+164.5%79.4%
VERAVera Therapeutics, Inc.Jun 2026$407.76M -12.9%+98.8%76.5%
NUVBNuvation Bio Inc.Jun 2026$253.86M -31.9%-22.4%34.1%
QUREuniQure N.V.Mar 2026$149.34M +343.3%-25.2%19.2%
Peer median (excluding NUVB) $655.78M+52.0%+17.4%78.5%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents132.42M101.1M42.65M35.72M164.09M
Short-term Investments632.97M559.92M568.56M466.97M365.13M
Net Receivables3.04M2.49M3.7M16.29M19.36M
Inventory000011.41M
Other Current Assets03.82M1.52M7.27M11.54M
Total Current Assets772.07M667.32M616.43M526.26M571.52M
Property, Plant & Equipment (Net)3.66M4.69M4.32M2.99M4.48M
Goodwill00000
Intangible Assets0004.62M11.21M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets421K138K728K6.76M7.61M
Total Non-current Assets4.08M4.82M5.05M14.37M23.3M
Total Assets776.15M672.14M621.48M540.63M594.82M
Account Payables3.93M2.14M2.21M6.35M9.48M
Short-term Debt0006.28M7.6M
Tax Payables402K112K144K679K0
Deferred Revenue00011.12M0
Other Current Liabilities6.17M3.99M4.35M14.82M65.15M
Total Current Liabilities16.93M13.16M13.97M58.24M82.23M
Long-term Debt00002.54M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00015.57M145.82M
Other Non-current Liabilities11.04M850K353K2.05M58.51M
Total Non-current Liabilities13.23M3.9M2.39M18.59M206.88M
Total Liabilities30.15M17.07M16.36M76.84M289.11M
Common Stock909.99M927.6M947.75M1.37B1.42B
Retained Earnings(162.8M)(267M)(342.8M)(910.74M)(1.12B)
Accumulated OCI(1.19M)(5.53M)181K573K(187K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity746M655.08M605.12M463.79M305.72M
Total Debt3.06M4.26M4.01M8.92M10.15M
Net Debt(129.37M)(96.84M)(38.64M)(26.81M)(153.94M)

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.